InterPAD - DETAILS

Sunitinib, 557795-19-4, Sutent, SU11248, SU-11248, sunitinibum, Su-011248, Sunitinib Base, 342641-94-5, (Z)-N-(2-(Diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide, Sunitinib (INN), Sunitinib [INN], NSC-750690, SU 11248, UNII-V99T50803M, CHEBI:38940, HSDB 7932, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, CHEMBL535, N-(2-(Diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide, NSC-736511, V99T50803M, SU011248, NSC750690, Sunitinib, Free base, NSC 736511, NSC 750690, 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, n-(2-(diethylamino)ethyl)-5-((z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl)-2,4-dimethyl-1h-pyrrole-3-carboxamide, N-(2-(DIETHYLAMINO)ETHYL)-5-((Z)-(5-FLUORO-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE, Sunitinib (free base), Sunitinib [INN:BAN], NCGC00164631-01, MFCD09260778, C22H27FN4O2, (Z)-Sunitinib, 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, 5-(5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide, 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide, Sutent (free base), KS-5022, SUNITINIB [MI], 1126641-10-8, SUNITINIB [VANDF], SCHEMBL8081, SUNITINIB [WHO-DD], SUNITINIB [EMA EPAR], BDBM4814, GTPL5713, Sutent, Sunitinib, SU11248, DTXCID9021134, CHEBI:91430, EX-A553, L01XE04, WINHZLLDWRZWRT-ATVHPVEESA-N, BCPP000057, K00588a, (E)-N-[2-(Diethylamono)ethyl]-5-[(5-fluoro-2-oxo-1,2-dihydro-3H-indole-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, HY-10255A, NSC800937, s7781, AKOS015908193, AKOS025312424, CCG-268638, CS-1670, DB01268, NSC-800937, NCGC00164631-02, NCGC00164631-04, 5-(5-fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, BD164426, 1,2,4,5-tetramethylpyrrole-3-carboxamide, AM20090630, FT-0651493, FT-0659515, NS00004661, D08552, EN300-323230, AB01273976-01, AB01273976-02, AB01273976_04, A822143, A830806, Q417542, SR-00000000005, SR-00000000005-2, Q27163278, Z2568722545, 1H-Pyrrole-3-carboxamide,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid(2-diethylamino-ethyl)-amide, N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1 pound not2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2 pound not4-dimethyl-1H-pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carbo

No.	Title	Href
1	Sunitinib and Pterostilbene Combination Treatment Exerts Antitumor Effects in Gastric Cancer via Suppression of PDZD8. Int J Mol Sci. 2022 Apr 4;23(7):4002. doi: 10.3390/ijms23074002.	`Click`
2	Targeting renal cell carcinoma with gambogic acid in combination with sunitinib in vitro and in vivo. Asian Pac J Cancer Prev. 2012;13(12):6463-8. doi: 10.7314/apjcp.2012.13.12.6463.	`Click`
3	Dihydroberberine exhibits synergistic effects with sunitinib on NSCLC NCI-H460 cells by repressing MAP kinase pathways and inflammatory mediators. J Cell Mol Med. 2017 Oct;21(10):2573-2585. doi: 10.1111/jcmm.13178.	`Click`

No.

Title

Href

Sunitinib and Pterostilbene Combination Treatment Exerts Antitumor Effects in Gastric Cancer via Suppression of PDZD8. Int J Mol Sci. 2022 Apr 4;23(7):4002. doi: 10.3390/ijms23074002.

Click

Targeting renal cell carcinoma with gambogic acid in combination with sunitinib in vitro and in vivo. Asian Pac J Cancer Prev. 2012;13(12):6463-8. doi: 10.7314/apjcp.2012.13.12.6463.

Click

Dihydroberberine exhibits synergistic effects with sunitinib on NSCLC NCI-H460 cells by repressing MAP kinase pathways and inflammatory mediators. J Cell Mol Med. 2017 Oct;21(10):2573-2585. doi: 10.1111/jcmm.13178.

Click

Name	Sunitinib
PubChem CID	5329102
Molecular Weight	398.5g/mol
Synonyms	Sunitinib, 557795-19-4, Sutent, SU11248, SU-11248, sunitinibum, Su-011248, Sunitinib Base, 342641-94-5, (Z)-N-(2-(Diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide, Sunitinib (INN), Sunitinib [INN], NSC-750690, SU 11248, UNII-V99T50803M, CHEBI:38940, HSDB 7932, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, CHEMBL535, N-(2-(Diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide, NSC-736511, V99T50803M, SU011248, NSC750690, Sunitinib, Free base, NSC 736511, NSC 750690, 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, n-(2-(diethylamino)ethyl)-5-((z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl)-2,4-dimethyl-1h-pyrrole-3-carboxamide, N-(2-(DIETHYLAMINO)ETHYL)-5-((Z)-(5-FLUORO-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE, Sunitinib (free base), Sunitinib [INN:BAN], NCGC00164631-01, MFCD09260778, C22H27FN4O2, (Z)-Sunitinib, 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, 5-(5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide, 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide, Sutent (free base), KS-5022, SUNITINIB [MI], 1126641-10-8, SUNITINIB [VANDF], SCHEMBL8081, SUNITINIB [WHO-DD], SUNITINIB [EMA EPAR], BDBM4814, GTPL5713, Sutent, Sunitinib, SU11248, DTXCID9021134, CHEBI:91430, EX-A553, L01XE04, WINHZLLDWRZWRT-ATVHPVEESA-N, BCPP000057, K00588a, (E)-N-[2-(Diethylamono)ethyl]-5-[(5-fluoro-2-oxo-1,2-dihydro-3H-indole-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, HY-10255A, NSC800937, s7781, AKOS015908193, AKOS025312424, CCG-268638, CS-1670, DB01268, NSC-800937, NCGC00164631-02, NCGC00164631-04, 5-(5-fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, BD164426, 1,2,4,5-tetramethylpyrrole-3-carboxamide, AM20090630, FT-0651493, FT-0659515, NS00004661, D08552, EN300-323230, AB01273976-01, AB01273976-02, AB01273976_04, A822143, A830806, Q417542, SR-00000000005, SR-00000000005-2, Q27163278, Z2568722545, 1H-Pyrrole-3-carboxamide,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid(2-diethylamino-ethyl)-amide, N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1 pound not2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2 pound not4-dimethyl-1H-pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carbo
Drug Type	Small molecule
Formula	C₂₂H₂₇FN₄O₂
SMILES	CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C
InChI	1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-
InChIKey	WINHZLLDWRZWRT-ATVHPVEESA-N
CAS Number	557795-19-4
ChEMBL ID	CHEMBL535
ChEBI ID	CHEBI:38940
TTD ID	D0R0MW
Drug Bank ID	DB01268
KEGG ID	D08552
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Pterostilbene, Sunitinib
Partner Name	Pterostilbene
Disease Info	[ICD-11: 2B72]	Gastric cancer		Investigative
Biological Phenomena	Induction-->Oxidative Stress
Gene Regulation	Down-regulation	Expression	PDZD8	hsa118987
In Vitro Model	TMK-1	Gastric adenocarcinoma	Homo sapiens (Human)	CVCL_4384
In Vitro Model	MKN74	Gastric tubular adenocarcinoma	Homo sapiens (Human)	CVCL_2791
In Vivo Model	Subcutaneous tumor models were established by inoculating cancer cells (MKN74: 5×10⁶ per mouse, TMK-1: 1×107 per mouse) into the scapular subcutaneous tissues of nude mice on Day 0.
Result	PDZD8 may be a newly discovered off-target for SUN, and that the combined use of PTE with SUN significantly promotes antitumor activity in gastric cancer cell lines. The combined use of SUN and PTE might be a new molecular-targeted therapy for gastric cancer.

Pair Name	Gambogic Acid, Sunitinib
Partner Name	Gambogic Acid
Disease Info	[ICD-11: 2C90.0]	Renal cell carcinoma		Investigative
Biological Phenomena	Inhibition-->Angiogenesis
Gene Regulation	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Expression	CDKN1A	hsa1026
	Down-regulation	Expression	VEGFA	hsa7422
In Vitro Model	786-O	Renal cell carcinoma	Homo sapiens (Human)	CVCL_1051
In Vitro Model	Caki-1	Clear cell renal cell carcinoma	Homo sapiens (Human)	CVCL_0234
In Vivo Model	Caki-1 cells (2×10⁶) in 100 ul RPMI-1640 and 100 ul of matrigel were used to inject subcutaneously into each mouse (5-week-old male athymic BALB/c nu/nu mice).
Result	Our results show that the joint use of GA and SU can provide greater antitumor efficacy compared to either drug alone and thus may offer a new treatment strategy for renal cell carcinoma.

Pair Name	Dihydroberberine, Sunitinib
Partner Name	Dihydroberberine
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Biological Phenomena	Induction-->Proliferation
Gene Regulation	Up-regulation	Expression	CCNB1	hsa891
	Up-regulation	Expression	CCND1	hsa595
	Down-regulation	Expression	CCNE1	hsa898
	Up-regulation	Expression	CDK1	hsa983
	Down-regulation	Expression	COX2	hsa4513
	Down-regulation	Expression	IKBKE	hsa9641
	Down-regulation	Expression	IL1B	hsa3553
	Down-regulation	Phosphorylation	MAPK14	hsa1432
	Down-regulation	Phosphorylation	MAPK8	hsa5599
	Down-regulation	Phosphorylation	NFKB1	hsa4790
In Vitro Model	A-549	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_0023
	NCI-H460	Lung large cell carcinoma	Homo sapiens (Human)	CVCL_0459
	NCI-H1299	Lung large cell carcinoma	Homo sapiens (Human)	CVCL_0060
In Vivo Model	Four to six‐week‐old non‐obese diabetic severe combined immunodeficiency (NOD/SCID) mice were injected subcutaneously into the right flank with 4×10⁶ NCI‐H460 cells suspended in sterile physiological saline.
Result	DCS induced the expression of cell cycle signal molecules that are known to be affected by JNK and p38. The change of cell cycle, in turn, led to down-regulation of JNK and p38, and further reduced IL-1 secretion. Collectively, these findings highlight potential molecular mechanisms of DCS chemotherapeutic activity and suggest that DCS is an efficacious strategy in NSCLC therapy.